Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inavolisib + cetuximab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Inavolisib + cetuximab** is an investigational combination therapy for cancer, currently being studied for metastatic colorectal cancer (mCRC) in patients intolerant to, or progressing after, standard therapies[1]. Inavolisib is a potent, selective oral inhibitor of PI3Kα (phosphoinositide 3-kinase alpha), with a unique ability to induce the degradation of mutant p110α protein, thus blocking PI3K pathway signaling implicated in tumor cell growth, survival, and proliferation[6][4][1]. Cetuximab is a monoclonal antibody that targets the extracellular domain of the Epidermal Growth Factor Receptor (EGFR), inhibiting receptor activation and tumor cell proliferation[7]. The combination is designed to target key oncogenic drivers: PI3K pathway dysregulation (inavolisib) and EGFR signaling (cetuximab), particularly for tumors with PIK3CA mutations (for inavolisib) and EGFR dependence (for cetuximab)[1][7].
- Other names
- inavolisib + cetuximab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on inavolisib + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inavolisib + cetuximab.